about
Human Immunodeficiency Virus as a Chronic Disease: Evaluation and Management of Nonacquired Immune Deficiency Syndrome-Defining ConditionsIncidence of hepatitis C virus (HCV) in a multicenter cohort of HIV-positive patients in Spain 2004-2011: increasing rates of HCV diagnosis but not of HCV seroconversionsEffects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized TrialThe CD4:CD8 ratio is associated with markers of age-associated disease in virally suppressed HIV-infected patients with immunological recoveryHIV-infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality.Altered metabolism of gut microbiota contributes to chronic immune activation in HIV-infected individuals.Gut Bacteria Metabolism Impacts Immune Recovery in HIV-infected IndividualsIL-15 promotes activation and expansion of CD8+ T cells in HIV-1 infection.Increased risk of serious non-AIDS-related events in HIV-infected subjects on antiretroviral therapy associated with a low CD4/CD8 ratio.The role of artesunate for the treatment of urinary schistosomiasis in schoolchildren: a systematic review and meta-analysis.Infections caused by carbapenemase-producing Enterobacteriaceae: risk factors, clinical features and prognosis.Prevalence of Elevated Blood Pressure in HIV-infected Children, Adolescents and Young Adults.HIV infection results in metabolic alterations in the gut microbiota different from those induced by other diseasesDifferent impact of raltegravir versus efavirenz on CD4/CD8 ratio recovery in HIV-infected patients.Bryostatin-1 for latent virus reactivation in HIV-infected patients on antiretroviral therapy.Decreasing prevalence of HCV coinfection in all risk groups for HIV infection between 2004 and 2011 in Spain.Development of tuberculosis in human immunodeficiency virus infected patients receiving antiretroviral therapy.Functionally defective high-density lipoproteins are related to heightened T-cell activation in vertically HIV-infected adolescents.Cardiovascular biomarkers in vertically HIV-infected children without metabolic abnormalities.Dynamics of the HIV-1 latent reservoir after discontinuation of the intensification of antiretroviral treatment: results of two clinical trials.Neutropenia during therapy with peginterferon and ribavirin in HIV-infected subjects with chronic hepatitis C and the risk of infections.The CD4/CD8 ratio as a marker T-cell activation, senescence and activation/exhaustion in treated HIV-infected children and young adults.Correction: Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial.[Etravirine drug interactions].Smoking cessation in HIV patients: rate of success and associated factors.Authors' Reply: association of HIV-infection and antiretroviral therapy with levels of endothelial progenitor cells and subclinical atherosclerosis.Association of HIV-Infection and antiretroviral therapy with levels of endothelial progenitor cells and subclinical atherosclerosis.Subclinical atherosclerosis and markers of immune activation in HIV-infected children and adolescents: the CaroVIH Study.The CD4/CD8 ratio in HIV-infected subjects is independently associated with T-cell activation despite long-term viral suppression.Screening for precancerous anal lesions with P16/Ki67 immunostaining in HIV-infected MSM.Diagnosis of subclinical atherosclerosis in HIV-infected patients: higher accuracy of the D:A:D risk equation over Framingham and SCORE algorithms.Interplay between gut microbiota metabolism and inflammation in HIV infectionFactores clínicos y biomarcadores asociados a lesión vascular subclínica en la infección por el virus de la inmunodeficiencia humanaIncipient Renal Impairment as a Predictor of Subclinical Atherosclerosis in HIV-Infected PatientsA 38 year old woman with hypotensive shock at the onset of menstruation: case outcomeCommentary: Managing clinician's assessment[Stroke in the very old: myths and realities][Reply]Analysis of the gut microbiota in alopecia areata: identification of bacterial biomarkersModulation of Saliva Microbiota through Prebiotic Intervention in HIV-Infected Individuals
P50
Q26740117-FA408936-6ECA-469B-909A-DEDEA6C5CACBQ28542942-492CDCEE-F40B-4FF6-95CC-26C6C133A8C9Q28552729-A57DFF9A-6651-4BD9-8069-01051E4C312DQ29307877-C4BF1A9B-4AC1-4437-ADCA-EA98EBD43E32Q33618542-585AB0BD-9061-44A0-B373-DCA59EBA989AQ35434347-B1294190-27CC-4D29-A71C-CC544EFFDDABQ36080200-3CD26A15-B78F-4C37-B535-833F56B5E9CAQ37042241-A6DEADB7-1B6F-48A2-A259-588E932406D5Q37534052-13A4259D-E7B1-4A66-BFD9-BF4A00BBC663Q37726847-1245AEB5-2330-4AC7-8AB4-F9A069739BD9Q38301152-9B6FF9C0-0D2B-4168-A178-06F4195D7165Q39422399-AF574955-FCA9-4FAC-93FD-E2ABF61F9FD5Q39758513-F53E17A7-F51B-4D3B-94D5-3D69C9214F79Q40531468-DB9C6773-7672-476C-99A2-7C1A780E2BA8Q40786377-FD36B8D7-8530-4B7B-B6AE-3298B0D51CDBQ41680569-20806DA4-E6A3-45F4-8460-AFE049074CD1Q41753227-115E34EC-68AA-4022-8339-DB75A3D70DCCQ42219365-B0962528-038A-4A6E-A538-1B1D9817099EQ42228249-4131F5CC-3386-4B37-A60A-42660E0B4A34Q42234468-157170DF-CA8D-4F69-BF5C-8045F4418AA8Q42267241-EAB70468-6573-47BB-96FA-99F222821B0AQ42273640-6D116E52-C66B-44E6-AFBC-9BF481FD019CQ42934696-4BB7594E-123C-4940-8468-463659FE4F31Q43179918-3A15C605-7ECE-4788-9D06-6FF2BB0FDBF6Q43297631-2C273831-B739-4AFA-ADB2-EB343FA96633Q43429588-94A7F753-936E-4BD7-B0D7-99E68372B746Q43508975-45F12F87-8188-4B15-9D60-607E4A6BBC7FQ44190495-CB1EAEF8-3323-42D3-975B-02D66D8BBA61Q44701988-7224850D-DBD2-48B0-BB97-5A701E35C3FDQ47096725-49EA90D6-C372-4EDC-B53E-E0CE20988FBDQ51352433-1E21A50D-4423-45B0-8ED5-43587593FD63Q58038972-58B25FAF-4539-4B28-9127-240CD796882CQ59118557-B42DF1B3-6036-4917-94B4-9D0FEA3E340AQ59118572-1637B3A2-6297-402D-8F21-BBAA5A1417BAQ83453526-0C02C081-71AF-473C-A0D4-976310EE75B1Q83453565-86969C40-C9BB-4A07-8657-E125686B5A1AQ84981981-48034912-EA7F-490A-A156-D1F983A6E718Q87387318-0D101384-14B3-4C7D-8E09-1AEBC2548F2CQ92661460-7980913B-9D62-478D-860A-EF1C5BE9B974Q92816010-D2E6BCED-7C5B-4A80-9CA2-D8C635565C99
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Sergio Serrano-Villar
@ast
Sergio Serrano-Villar
@en
Sergio Serrano-Villar
@es
Sergio Serrano-Villar
@nl
Sergio Serrano-Villar
@sl
type
label
Sergio Serrano-Villar
@ast
Sergio Serrano-Villar
@en
Sergio Serrano-Villar
@es
Sergio Serrano-Villar
@nl
Sergio Serrano-Villar
@sl
prefLabel
Sergio Serrano-Villar
@ast
Sergio Serrano-Villar
@en
Sergio Serrano-Villar
@es
Sergio Serrano-Villar
@nl
Sergio Serrano-Villar
@sl
P106
P21
P31
P496
0000-0002-5447-3554